NASDAQ - NuCana plc

График котировок NuCana plc


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/BV 2.2
Цена ао 4.31
EV/EBITDA -4.12
EBITDA -0.0324

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 0
P/BV 2.2 5
P/E 0
EV/EBITDA -4.12 10

Эффективность

Название Значение Оценка
ROA, % -23.13 1
ROE, % -37.7 1

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 10

Импульс роста

Название Значение Оценка
Рост прибыли, % 26.74 5
Рост цены акции, % -63.85 0
Рост дивидендов, % 0 0

Основные владельцы

Институционалы Объем Доля, %
Capital Research and Management Company 15591722 30.47
Sofinnova Ventures 5599999 10.94
Capital Research & Mgmt Co - Division 3 4417153 8.63
Abingworth LLP 3333333 6.51
Baillie Gifford & Co Limited. 3319330 6.49
Capital Guardian Trust Company 2977153 5.82
Harvard Management Co Inc 1678239 3.28
Sectoral Asset Management Inc 750000 1.47
Granite Point Capital Management LP 644608 1.26
Asymmetry Capital Management, L.P. 613769 1.2
Tekla Capital Management LLC 460672 0.9
Monashee Investment Management LLC 400000 0.78
Infinity Q Capital Management, LLC 162478 0.32
BBVA Asset Management SA SGIIC 130000 0.25
Wildcat Capital Management, LLC 127806 0.25
JPMorgan Asset Management (Europe) S.à r.l. 101282 0.2
Anson Funds Management LP 69632 0.14
ALPS Advisors Inc 57118 0.11
JP Morgan Alternative Asset Mgmt Inc 38318 0.07
CVI Holdings LLC 33803 0.07
SSGA Funds Management Inc 14368 0.03
Plante Moran Financial Advisors LP 6000 0.01
Eagle Asset Management, Inc. 5247 0.01

Похожие компании

Описание NuCana plc

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.